Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atai Life Sciences N.V. (NQ: ATAI )

1.480 -0.050 (-3.27%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Atai Life Sciences N.V.

< Previous 1 2
...
17 18 19 20 21 22 23 24 Next >
Can Ibogaine Treat Opioid Addiction? Nasdaq-Listed Atai Is Launching A Trial To Find Out
DemeRx IB, Inc., a company developing psychedelic ibogaine for the treatment of opioid use disorder, has begun a phase 1/2... 
Via Benzinga
Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial
AdvisorShares Launches First NYSE-listed Actively-managed Psychedelics ETF On Thursday, AdvisorShares 
Via Benzinga
Can Ketamine For Depression Be Improved? New Study Will Looks Into Ketamine Analog Arketamine
Perception Neuroscience, an Atai Life Sciences (NASDAQ:ATAI) subsid... 
Via Benzinga
Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics
Last Week In Psychedelics: 
Via Benzinga
Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry?
By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate... 
Via Benzinga
Where ATAI Life Sciences Stands With Analysts
ATAI Life Sciences (NASDAQ:ATAI) has observed the followi... 
Via Benzinga
What 9 Analyst Ratings Have To Say About ATAI Life Sciences
ATAI Life Sciences (NASDAQ:ATAI) has observed the following analyst rating... 
Via Benzinga
Psychedelic Drug Industry Report Card For 2021
In assessing the psychedelic drug industry, a primary focus for investors is drug development. 
Via Talk Markets
What 10 Analyst Ratings Have To Say About ATAI Life Sciences
Analysts have provided the following ratings for ATAI Life Sciences (NASDAQ:AT... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2021
Upgrades For Chatham Lodging Trust (NYSE: 
Via Benzinga
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
21 Stocks Moving in Wednesday's Pre-Market Session
Gainers GBS Inc. (NASDAQ: GBS) rose 72.3% to $5.58 in pre-market trading. The company markets saliva test for diabetes management and previously announced collaboration on covid-... 
Via Benzinga
Psyched: Atai Launches 'Salvia Divinorum' Subsidiary, Mindset, Psilera and Wesana's Preclinical Trials, Origin Raises $5M
Atai Life Sciences Launches New Salvia Divinorum Subsidiary Atai Life Sciences (NASDAQ: 
Via Benzinga
Peter Thiel Backed Atai Life Launches New Mental Health Disorders-Focused Company
Peter Thiel-backed Atai Life Sciences (NASDAQ: ATAI) has launched a new portfolio company, Revixia Life Sciences. Revixia Life's primary mission is to... 
Via Benzinga
Atai Life Sciences To Research Potent Psychedelic Herb Salvia Divinorum Through Its New Subsidiary
Atai Life Sciences (NASDAQ:ATAI) has announced the launch ... 
Via Benzinga
Understanding ATAI Life Sciences's Unusual Options Activity
On Wednesday, shares of ATAI Life Sciences (NASDAQ:ATAI) s... 
Via Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Exposures COVID-19
Earnings Scheduled For August 16, 2021
Companies Reporting Before The Bell • Entera Bio (NASDAQ:ENTX) is likely to report earnings for its second quarter. • Data Storage (NASDAQ:DTST) is expected to... 
Via Benzinga
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures COVID-19
Stocks That Hit 52-Week Lows On Monday
Before 10 a.m. ET Monday, 63 stocks made new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was PACCAR (NASDAQ:PCAR).... 
Via Benzinga
Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected
Last week in Psychedelics: 
Via Benzinga
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning session, 77 companies made new 52-week lows. Areas of Interest: The largest company in terms of market cap to set a new 52-week low... 
Via Benzinga
Another Psychedelic Stock Debuts, As This One Sets Up In A Base
Field Trip Health dipped in its first day on the Nasdaq, making it the latest psychedelics company to hit a big U.S. exchange. 
Via Investor's Business Daily
Atai Launches New "Nose-To-Brain" Drug Delivery Company To Interact With Its Portfolio Of Psychedelics Subsidiaries
Atai Life Sciences (NASDAQ:ATAI) is launching a new company 
Via Benzinga
Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To "Psychedelics Renaissance"
Excitement around psychedelics grows as major U.S. exchanges make room for more companies in the sector. On Friday, 
Via Benzinga
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
< Previous 1 2
...
17 18 19 20 21 22 23 24 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.